An Evaluation of Long-Term Supplement Use on Biological Age and Metabolic Health Markers - The BioAge Trial

计划入组 300 人 · 首次发布于 2026 年 8 月 10 日

The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

计划入组 100 人 · 首次发布于 2022 年 9 月 2 日

Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

计划入组 80 人 · 首次发布于 2010 年 6 月 16 日

NLRP3 inhibitors(Bioage)

BioAMB

BINATE

BioAge Labs, Inc.

United States

BioVie

United States

Biowave Corporation

United States

BioAge Labs Halts Azelaprag Trial Due to Safety Concerns, Faces Investor Scrutiny

BioAge Labs Faces Securities Lawsuits Following Azelaprag Trial Discontinuation

BioAge Labs Shifts Focus to NLRP3 Inhibitor After Azelaprag Trial Discontinued